Can-Fite Biopharma shares surge 38.66% premarket after securing Brazilian patent for A3 adenosine agonists in sexual dysfunction treatment.

Can-Fite BioPharma surged 38.66% in premarket trading following the announcement that the Brazilian Patent Office granted a patent for its A3 adenosine receptor agonists to treat sexual dysfunction. This development expands the company’s intellectual property portfolio in Brazil, a significant pharmaceutical market in Latin America, and underscores the therapeutic versatility of its drug candidates. The patent strengthens the rationale for commercialization or partnership opportunities in Brazil, where demand for innovative sexual health therapies is growing. The positive news aligns with the stock’s sharp premarket rise, driven by investor optimism over the patent’s potential to enhance the company’s market position and pipeline value.